2021
Predictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study.
He L, Qin Y, Xu Y, Hu S, Wang Y, Zeng M, Feng X, Liu Q, Syed I, Demuyakor A, Zhao C, Chen X, Li Z, Meng W, Xu M, Liu H, Ma L, Dai J, Xing L, Yu H, Hou J, Jia H, Mintz G, Yu B. Predictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study. EuroIntervention 2021, 17: 497-505. PMID: 33164894, PMCID: PMC9724919, DOI: 10.4244/eij-d-20-00299.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeCoronary AngiographyHumansPlaque, AtheroscleroticStentsTomography, Optical CoherenceTreatment OutcomeConceptsAcute coronary syndromeNon-TLR groupLong-term prognosisOptical coherence tomographyFollow-upAntithrombotic therapyCoronary syndromePredictor of long-term prognosisResponse to antithrombotic therapyTreated with antithrombotic therapyPlaque erosionLong-term follow-upTarget lesion revascularisationMedian durationPrimary endpointAntithrombotic strategiesOne-month follow-upThrombus reductionGastrointestinal bleedingAngiographic resultsCoherence tomographyStent implantationDiameter stenosisClinic visitsPatientsIs the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging
Xu M, Demuyakor A, Hu S, Liu H, Zhao C, Chen T, Qin Y, Xu Y, Feng X, Zeng M, Weng Z, Gao Z, Hou J, Jia H, Zhang S, Yu B. Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging. Catheterization And Cardiovascular Interventions 2021, 97: 1097-1107. PMID: 33864710, DOI: 10.1002/ccd.29654.Peer-Reviewed Original ResearchConceptsOptical coherence tomographyLipid-rich plaquesLipid lowering therapyEffect of atorvastatinFibrous cap thicknessStatin therapyLowering therapyCoherence tomographyIntensive lipid lowering therapySerial optical coherence tomographyCholesterol levelsLow-density lipoprotein cholesterol levelsIntravascular ultrasound imagingLipoprotein cholesterol levelsCholesterol level reductionLipid arcClinical benefitFollow-upPlaque volumeUltrasound imagingTherapyTherapy effectsPlaque burdenPercentage changeStatins
2018
Does spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study
Afolabi A, Mustafina I, Zhao L, Li L, Sun R, Hu S, Zhang S, Jia H, Guilio G, Yu B. Does spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study. Catheterization And Cardiovascular Interventions 2018, 91: 582-590. PMID: 29359491, DOI: 10.1002/ccd.27496.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary AngiographyCoronary Artery DiseaseCoronary VesselsFemaleFibrosisHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTomography, Optical CoherenceTreatment OutcomeVascular CalcificationConceptsStatin therapyOptical coherence tomographyFibrous cap thicknessSpotty calcificationIntensity statinsModerate statin therapyPresence of spotty calcificationBaseline to 6Lipid-rich plaquesModerate statinsLipid arcCalcification groupCoherence tomographyStatinsTherapyPlaque characteristicsPlaque stabilityCalcificationPlaque progressionMonthsPlaquePatientsVulnerable plaquesMarkers of vulnerable plaqueBaseline